Hosted by Dr. Viorica Chelban and the Queen Square Institute of Neurology, University College London. An event focusing on the latest basic science and clinical research into Multiple System Atrophy, this year’s symposium will bring the latest research based on MSA genetics, biomarkers in MSA, alpha-synuclein structures in human brain and MSA and new diagnostic and prognostic factors in MSA. Four new MSA drug trials will be announced during the day and CPD points will also be awarded to attendees after the event.

We are delighted to have such a knowledgeable line up of presenters, who will include Dr Michel Goedert, Dr Tim Bartels, Prof Christos Proukakis, Prof Henry Houlden Prof Jalesh Panicker, Dr Dr Valeria Iodice, Dr Yee Yen Goh, Dr Viorica Chelban, Dr Conceicao Bettencourt, Dr Mina Ryten, Dr Chris Kobylecki, Prof Thomas Foltynie, Prof Huw Morris and Dr Christian Lambert. It promises to be a very interesting and provocative event. Sessions will be packed with interesting recent research and will include:

• Alpha-synuclein structures in human brain and MSA focussing on Cryo-EM structures of alpha-synuclein filaments from human brains
• Alpha-synuclein and MSA genetics covering latest research on somatic structural variants in MSA, brain, abnormal brain DNA methylation to new α‐synuclein ‘partners in crime’ and SNCA expression in MSA
• Biomarkers in MSA panel will discuss established biomarkers that predict neurodegeneration and progression in MSA, biomarkers discriminating the alpha-synuclein strains in MSA and PD, development of an early diagnostic test for MSA using multiple blood-based biomarkers and advanced anatomical MRI for Parkinsonian disorders
• Towards improving diagnosis and prognosis of MSA session will discuss the diagnosis of MSA in the early stages: implications of the new diagnostic criteria, autonomic biomarkers and early diagnosis in MSA, PROSPECT-M Study Progression and prognostic factors in MSA, and Gastrostomy insertion and outcomes in MSA and other atypical parkinsonian syndromes
• New horizons in MSA drug trials session will announce the opening of four new drug trials: Targeting the primary pathology in MSA, A randomized, double-blind, placebo-controlled study of ATH434 in MSA; the Phase 3 Ampreloxetine trial and updates on the trial of Exenatide as a potential disease modifying treatment in MSA.

Refreshments and complimentary hot lunch provided. 

Register for your ticket via Eventbrite, prices start at £27.80